TrialBritish journal of cancer2006

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

A R Clamp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.